Simplify Logo

Full-Time

Senior/Principal Scientist

Pharmaceutical Development

Confirmed live in the last 24 hours

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Biotechnology firm specializing in antibody therapies

Data & Analytics
Hardware
AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$110k - $173kAnnually

+ Equity + Annual Bonus + RRSP Contribution + Active Lifestyle Allowance

Senior, Expert

Vancouver, BC, Canada

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • You hold a Ph.D. and 10+ years of experience, M.Sc. or B.Sc. and 15+ years of experience in formulation, drug product and in-use stability development with monoclonal antibodies or related biotherapeutic antibodies
  • You have proven experience leading a team including mentoring, team professional development and goal alignment with and across teams
  • You have expertise in biophysical or biochemical characterization of proteins and degradation pathways
  • You have experience authoring drug product sections of regulatory filings such as INDs, IMPDs, etc. and familiarity with regulatory requirements (FDA, EMA, ICH, etc)
  • You have a passion for science with a motivation for making contributions in a team environment
  • You thrive in a fast-paced environment and are able to balance multiple projects and challenging priorities
Responsibilities
  • Providing strategic, technical and tactical leadership for the Formulation Development team
  • Developing antibody formulation and drug product process development, and clinical in-use compatibility strategies in alignment with regulatory guidelines and business objectives
  • Contributing to multiple concurrent projects either directly as a subject matter expert or through mentoring and coordinating resource support
  • Representing the formulation function on internal and external CMC teams; contributing to the product control strategy as it relates to formulation and drug product development
  • Providing leadership on interpretation of analytical results to understand antibody degradation pathways and developing strategies to maximize product stability
  • Providing functional area data review, analysis, and troubleshooting for data generated by internal and contract labs
  • Authoring and reviewing technical reports and regulatory submissions
  • Streamlining the activities associated with a wide variety of formulation technologies and data analysis strategies to shorten development times and improve the quality of formulations being delivered
  • Building and managing partnerships with research, non-clinical, clinical, drug substance process development, analytical development, and quality
  • Providing support, mentorship, and training to junior staff

AbCellera specializes in discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera focuses on challenging targets that traditional methods struggle to address. The company aims to accelerate the development of new medicines through collaborations, generating revenue from discovery services, licensing agreements, and its own therapeutic programs.

Company Stage

Series A

Total Funding

$393.1M

Headquarters

Vancouver, Canada

Founded

2012

Growth & Insights
Headcount

6 month growth

2%

1 year growth

0%

2 year growth

33%
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic collaborations with firms like Viking Global Investors and Biogen expand AbCellera's capabilities and market opportunities.
  • AbCellera's participation in high-profile industry conferences and presentations, such as AACR, showcases its cutting-edge research and strengthens its industry reputation.
  • The company's internal pipeline of therapeutic programs offers potential for significant breakthroughs and new treatments.

What critics are saying

  • The highly competitive and rapidly evolving biopharmaceutical market requires continuous innovation to maintain a competitive edge.
  • The recent resignation of board member Peter Thiel could lead to strategic and governance challenges.

What makes AbCellera Biologics unique

  • AbCellera's proprietary technology platform accelerates antibody discovery, making it faster and more efficient than traditional methods.
  • The company's ability to tackle challenging targets that have been difficult to address with traditional methods sets it apart in the biopharmaceutical market.
  • AbCellera's collaborative business model, which includes partnerships with leading investment firms and biotech companies, enhances its innovation and market reach.